Pharmaceutical giant GlaxoSmithKline (GSK ... increase for HIV treatments and 98% increase for oncology drugs. Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for ...

By providing relatively low priced drugs, many customers' segments have access to GSK products ... The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other ...

GSK has upgraded its long-term sales target after demand for its HIV and oncology drugs lifted the pharma giant to a better-than-anticipated fourth quarter. The FTSE 100 group is now targeting ...

(Bloomberg) -- GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks ... stage development of several oncology drugs, though vaccine sales are falling.

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE ... advancements in therapeutic ...